Travel-Related Illness
Conditions
Keywords
Travel, Risk Factors, Pathology, Arbovirose
Brief summary
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues. The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Detailed description
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues. The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory. Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern. To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR. * EOP-Arbo : The objective of this sub-study is to determine the risk of contracting an arboviral disease during travel, as well as the factors that may favor infection. For this, blood samples will be collected. * EOP-AMR : The objective of this sub-study is to determine the risk of contracting an antibiotic-resistant bacteria during the trip. For this, faecal samples will be collected.
Interventions
OTHERBlood sample collection
16 mL at inclusion 16 mL at 1 month after return from travel
1 sample at inclusion 1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel
Sponsors
Institut Pasteur
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Inclusion Criteria : 1. For all participants in the EOP study : * Major subject (age ≥ 18) * Owns a smartphone compatible with electronic data collection * Preparing to travel outside mainland France * Affiliated with or covered by Social Security or private insurance * Willing to participate in the EOP study 2. For the EOP-Arbo Sub-study : \- Subject who has consented to participate in the EOP\_Arbo study. 3. For the EOP-AMR Sub-study : * Subject who has consented to participate in the EOP\_AMR study. 2.
Exclusion criteria
1. For all participants in the EOP study : * Travel duration ≤ 3 days * Travel duration \> 12 months * Person traveling as part of an expatriation without planned movement outside the settlement in the destination country * Person under legal protection or unable to express consent for participation 2. For the EOP-Arbo Sub-study : \- Individuals deemed clinically and/or biologically unfit by the investigator to undergo the blood samples required for the study. 3. For the EOP-AMR Sub-study : * No specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the incidence of pathologies occurring during a travel outside the metropolitan territory. | 10 years | Number of subjects who developed a pathology during the travel among participants |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| For EOP-Arbo sub-study : Determine the prevalence for the occurrence of an arboviral disease (dengue, chikungunya, Zika) during the travel. | 10 years | Number of arboviral diseases (dengue, chikungunya, Zika) during the travel among participants |
| For EOP-AMR sub-study : Determine the prevalence for the acquisition of multi-resistant bacteria (MRB) during the travel. | 10 years | Proportion of subjects with multi-resistant bacteria acquired during the travel |
Countries
France
Contacts
Primary ContactFabien TAIEB, MD
Backup ContactJulia ABAD
Outcome results
None listed